ARTICLE | Clinical News
Olysio simeprevir regulatory update
March 24, 2014 7:00 AM UTC
EMA's CHMP backed approval of an MAA from Johnson & Johnson for Olysio simeprevir to treat HCV genotypes 1 and 4 infection in adults in combination with other drugs, including interferon and ribavirin...